Maxim Group Upgrades Virpax Pharmaceuticals to Buy, Announces $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Naz Rahman has upgraded Virpax Pharmaceuticals (NASDAQ:VRPX) from Hold to Buy and set a price target of $3.
July 19, 2024 | 1:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Maxim Group analyst Naz Rahman has upgraded Virpax Pharmaceuticals from Hold to Buy and set a price target of $3.
The upgrade from Hold to Buy and the announcement of a $3 price target by a reputable analyst is likely to positively impact the stock price of Virpax Pharmaceuticals in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100